News

The UK Government Announces its First-Ever Grant to the Aeras Global TB Vaccine Foundation


22 Mar 2010
by Working Group

aeras
www.aeras.org

8 million GBP will support the fight against tuberculosis

Rockville, Maryland, USA, March 23, 2010 – Global efforts to combat tuberculosis gained momentum today when the government of the United Kingdom announced generous funding to the Aeras Global TB Vaccine Foundation. The first-ever grant of £ 8,000,000 (approximately US$ 13 million) is a significant show of support for Aeras in its mission to develop new TB vaccines.

“If the international community is serious about tackling HIV and TB we must find a way to break this devastating cycle,” said Mike Foster, the UK Minister for International Development.” That is why the UK is supporting the discovery of a new TB vaccine that is safe for babies born with HIV, and why we are scaling up efforts to reduce the impact of drug resistant strains of TB.”

“Investment by the UK government in our TB vaccine development program is a tremendous boost for Aeras and our partners, especially during such a difficult economic environment,” said R. Gordon Douglas, Jr., MD, Executive Chairman of the Aeras Global TB Vaccine Foundation. “We are grateful to DFID for this generous support.”

> click here to read the press release

More News
22 Jul 2024
The National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) has issued a $30.8 million grant to the Preclinical Design and Clinical Translation of TB Regimens (PreDiCTR) consortium , a new consortium co-led by investigators from Weill Cornell Medicine; the...
27 Jun 2024
On May 17, the World Health Organization (WHO) released its updated  Bacterial Priority Pathogens List (BPPL) 2024 and for the first time in its history it included a drug resistant strain of Mycobacterium tuberculosis. Along with three other new families of antibiotic-resistant bacterial pathogens...
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...